Skip to main content
SpringerLink
Log in

Inhibition of human cytochrome P450 isoenzymes by a phenothiazine neuroleptic levomepromazine: An in vitro study

  • Short communication
  • Published:
Pharmacological Reports Aims and scope Submit manuscript

Abstract

Background

Inhibition of cytochrome P450 (CYP) isoenzymes is the most common cause of harmful drug–drug interactions. The present study was aimed at examining the inhibitory effect of the phenothiazine neuroleptic levomepromazine on main CYP isoenzymes in human liver.

Methods

The experiment was performed in vitro using the human cDNA-expressed CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 (Supersomes). CYP isoenzyme activities were determined using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A2), diclofenac 4′-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19), bufuralol 1′-hydroxylation (CYP2D6) and testosterone 6β-hydroxylation (CYP3A4). The rates of the CYP-specific reactions were assessed in the absence and presence of levomepromazine (1–50 μM). The concentrations of CYP-specific substrates and their metabolites formed by CYP isoenzymes were measured by HPLC with UV or fluorimetric detection.

Results

Levomepromazine potently inhibited CYP2D6 (K i = 6 μM) in a competitive manner. Moreover, the neuroleptic moderately diminished the activity of CYP1A2 (Ki = 47 μM) and CYP3A4 (Ki = 34 μM) via a mixed mechanism. On the other hand, levomepromazine did not affect the activities of CYP2C9 and CYP2C19.

Conclusion

The inhibition of CYP1A2, CYP2D6 and CYP3A4 by levomepromazine, demonstrated in vitro in the present study, should also be observed in vivo (especially the CYP2D6 inhibition by levomepromazine), since the calculated Ki values are below or close to the presumed concentration range for levomepromazine in the liver in vivo. Therefore pharmacokinetic interactions involving levomepromazine and CYP2D6, CYP1A2 or CYP3A4 substrates are likely to occur in patients during co-administration of the above-mentioned substrates/drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008;82:667–715.

    Article  CAS  Google Scholar 

  2. Green B, Pettit T, Faith L, Seaton K. Focus on levomepromazine. Curr Med Res Opin 2004;20:1877–81.

    Article  CAS  Google Scholar 

  3. Dietz I, Schmitz A, Lampey I, Schulz C. Evidence for the use of levomepromazine for symptom control in the palliative care setting: a systematic review. BMC Palliat Care 2013;12:2.

    Article  Google Scholar 

  4. Wójcikowski J, Basińska A, Daniel WA. The cytochrome P450-catalyzed metabolism of levomepromazine, a phenothiazine neuroleptic with a wide spectrum of clinical application. Biochem Pharmacol 2014;90:188–95.

    Article  Google Scholar 

  5. Wójcikowski J, Basińska A, Boksa J, Daniel WA. The influence of amitriptyline and carbamazepine on levomepromazine metabolism in human liver: an in vitro study. Pharmacol Rep 2014;66:1122–6.

    Article  Google Scholar 

  6. Kallio J, Huupponen R, Seppälä M, Säkö E, Iisalo E. The effects of β-adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine. Br J Clin Pharmacol 1990;30:638–43.

    Article  CAS  Google Scholar 

  7. Syvälahti EKG, Lindberg R, Kallio J, De Vocht M. Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 1986;22:89–92.

    PubMed  PubMed Central  Google Scholar 

  8. Vevelstad M, Pettersen S, Tallaksen C, Brørs O. O-demethylation of codeine to morphine inhibited by low-dose levomepromazine. Eur J Clin Pharmacol 2009;65:795–801.

    Article  CAS  Google Scholar 

  9. Gervasini G, Caballero MJ, Carillo JA, Benitez J. Comparative cytochrome P450 in vitro inhibition by atypical antipsychotic drugs. ISRM Pharmacol 2013 [Article ID 792456].

  10. Daniel WA, Kot M, Wójcikowski J. Influence of classic and atypical neuroleptics on caffeineoxidation in rat liver microsomes. Pol J Pharmacol 2003;55:1055–61.

    Article  CAS  Google Scholar 

  11. Schmitz G, Lepper H, Estler CJ. High-performance liquid chromatographic method for the routine determination of diclofenac and its hydroxyl and methoxy metabolites from in vitro systems. J Chromatogr 1993;620:158–63.

    Article  CAS  Google Scholar 

  12. Wójcikowski J, Pichard-Garcia L, Maurel P, Daniel WA. The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol 2004;14:199–208.

    Article  Google Scholar 

  13. Hiroi T, Chow T, Imaoka S, Funae Y. Catalytic specificity of CYP2D isoforms in rat and human. Drug Metab Dispos 2002;30:970–6.

    Article  CAS  Google Scholar 

  14. Wójcikowski J, Haduch A, Daniel WA. Effect of classic and atypical neuroleptics on cytochrome P450 3A (CYP3A) in rat liver. Pharmacol Rep 2012;64:1411–8.

    Article  Google Scholar 

  15. Dinovo EC, Bost RO, Sunshine I, Gottschalk LA. Distribution of thioridazine and its metabolites in human tissues and fluids obtained postmortem. Clin Chem 1978;24:1828–30.

    CAS  PubMed  Google Scholar 

  16. Wójcikowski J, Daniel WA. Distribution interactions between perazine and antidepressant drugs. In vivo studies. Pol J Pharmacol 2000;52:449–57.

    PubMed  Google Scholar 

  17. Kudo K, Inoue H, Ishida T, Tsuji A, Ikeda N. A fatal case of amoxapine poisoning under the influence of chronic use of psychotropic drugs. Leg Med 2007;9: 63–67.

    Article  CAS  Google Scholar 

  18. Lydiard RB, Gelenberg AJ. Amoxapine-an antidepressant with some neuroleptic properties?A review of its chemistry, animal pharmacology and toxicology, human pharmacology, and clinical efficacy. Pharmacotherapy 1981;1:163–78.

    Article  CAS  Google Scholar 

  19. Daniel WA, Haduch A, Wójcikowski J. Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo-possible involvement of different mechanisms. Eur Neuropsychopharmacol 2005;15:103–10.

    Article  CAS  Google Scholar 

  20. Kobayashi S, Murray S, Watson D, Sesardic D, Davies DS, Boobis AR. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem Pharmacol 1989;38:2795–9.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland

    Agnieszka Basińska-Ziobroń, Władysława A. Daniel & Jacek Wójcikowski

Authors
  1. Agnieszka Basińska-Ziobroń
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Władysława A. Daniel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jacek Wójcikowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacek Wójcikowski.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Basińska-Ziobroń, A., Daniel, W.A. & Wójcikowski, J. Inhibition of human cytochrome P450 isoenzymes by a phenothiazine neuroleptic levomepromazine: An in vitro study. Pharmacol. Rep 67, 1178–1182 (2015). https://doi.org/10.1016/j.pharep.2015.04.005

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.pharep.2015.04.005

Keywords

Search

Navigation